This document was published more than 2 years ago. The nature of the evidence may have changed.
Venous thromboembolism (VTE) causes more than 1 000 deaths and leads to the admission to hospital of 11 000 patients each year in Sweden. Prevention of venous thrombosis and pulmonary embolism is therefore of great importance. Diagnosis is difficult as the symptom profile is diffuse and difficult to interpret. Acute treatment and secondary prophylaxis are complicated as the risk of severe bleeding is great. In 1999, the costs to the Swedish society for diseases caused by venous thromboembolism were estimated to exceed 0.5 billion SEK. We systematically reviewed the literature on prevention, diagnosis and treatment of VTE.
Data sources: Medline and Cochrane Library up to July 2001, reference lists, personal communications.
Review methods: We included only randomized controlled studies and to assess diagnostic methods, only studies with an independent comparison with a known reference method. Approximately 1300 scientific studies met the requirements for high scientific quality.
The scientific evidence strongly suggests that low molecular weight heparin can replace unfractionated heparin in preventing and treating venous thrombosis and pulmonary embolism. Treatment with a single daily injection, rather than two, of low molecular weight heparin yields equally favorable effects. The risk for hemorrhage is lower with low molecular weight heparin and management is simpler, which facilitates outpatient treatment. Longer-term secondary prophylaxis with warfarin reduces the risk for relapse, but several years of treatment also increases the risk for severe hemorrhage.
The presence of treatment-demanding VTE can be excluded in outpatients by combining the assessment of clinical probability, using clinical decision rules, with measurement of D-dimer. Thorough ultrasonic examination of the leg and a CT scan of the pulmonary vessels usually provide sufficient diagnostic reliability – which strongly supports the use of these methods in clinical practice.
It is not meaningful to conduct extensive investigations of patients with venous thrombosis to find possible underlying cancer. It is essential to develop more cost-effective methods to investigate genetic predisposition for thrombosis.
How to cite this report:
SBU. Prevention, diagnosis, and treatment of venous thromboembolism. Stockholm: Swedish Council on Health Technology Assessment in Health Care (SBU); 2003. SBU report no 158/1 (in Swedish).
SBU. Prevention, diagnosis, and treatment of venous thromboembolism. Stockholm: Swedish Council on Health Technology Assessment in Health Care (SBU); 2003. SBU report no 158/2 (in Swedish).
SBU. Prevention, diagnosis, and treatment of venous thromboembolism. Stockholm: Swedish Council on Health Technology Assessment in Health Care (SBU); 2003. SBU report no 158/3 (in Swedish).
presents a comprehensive, systematic assessment of available scientific evidence. The certainty of the evidence for each finding is systematically reviewed and graded. Full assessments include economic, social, and ethical impact analyses.
SBU assessments are performed by a team of leading professional practitioners and academics, patient/user representatives and SBU staff. Prior to approval and publication, assessments are reviewed by independent experts, SBU’s Scientific Advisory Committees and Board of Directors.
|Report no:||158 (3 vol)|